![logo](/logos/ANP.AX.webp)
Antisense Therapeutics Limited
ASX:ANP.AX
0.06 (AUD) • At close January 3, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Antisense Therapeutics Limited |
Symbool | ANP.AX |
Munteenheid | AUD |
Prijs | 0.058 |
Beurswaarde | 52,289,611 |
Dividendpercentage | 0% |
52-weken bereik | 0.05 - 0.11 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA |
Website | https://www.antisense.com.au |
An error occurred while fetching data.
Over Antisense Therapeutics Limited
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)